Literature DB >> 25845862

Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.

Mariana Castanheira1, Janet C Mills2, Sarah E Costello2, Ronald N Jones2, Helio S Sader2.   

Abstract

Ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) inhibited 99.9% (20,698/20,709) of Enterobacteriaceae isolates at ≤8 μg/ml. This compound was active against resistant subsets, including ceftazidime-nonsusceptible Enterobacter cloacae (MIC50/90, 0.25/0.5 μg/ml) and extended-spectrum β-lactamase (ESBL) phenotype isolates. An ESBL phenotype was noted among 12.4% (1,696/13,692 isolates from targeted species) of the isolates, including 776 Escherichia coli (12.0% for this species; MIC50/90, 0.12/0.25 μg/ml), 721 Klebsiella pneumoniae (16.3%; MIC50/90, 0.12/0.25 μg/ml), 119 Klebsiella oxytoca (10.3%; MIC50/90, 0.06/0.25 μg/ml), and 80 Proteus mirabilis (4.9%; MIC50/90, 0.06/0.12 μg/ml) isolates. The most common enzymes detected among ESBL phenotype isolates from 2013 (n = 743) screened using a microarray-based assay were CTX-M-15-like (n = 307), KPC (n = 120), SHV ESBLs (n = 118), and CTX-M-14-like (n = 110). KPC producers were highly resistant to comparators, and ceftazidime-avibactam (MIC50/90, 0.5/2 μg/ml) and tigecycline (MIC50/90, 0.5/1 μg/ml; 98.3% susceptible) were the most active agents against these strains. Meropenem (MIC50/90, ≤0.06/≤0.06 μg/ml) and ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) were active against CTX-M-producing isolates. Other enzymes were also observed, and ceftazidime-avibactam displayed good activity against the isolates producing less common enzymes. Among 11 isolates displaying ceftazidime-avibactam MIC values of >8 μg/ml, three were K. pneumoniae strains producing metallo-β-lactamases (all ceftazidime-avibactam MICs, >32 μg/ml), with two NDM-1 producers and one K. pneumoniae strain carrying the bla(KPC-2) and bla(VIM-4) genes. Therapeutic options for isolates producing β-lactamases may be limited, and ceftazidime-avibactam, which displayed good activity against strains, including those producing KPC enzymes, merits further study in infections where such organisms occur.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25845862      PMCID: PMC4432207          DOI: 10.1128/AAC.00163-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Spectrophotometry-based detection of carbapenemase producers among Enterobacteriaceae.

Authors:  Sandrine Bernabeu; Laurent Poirel; Patrice Nordmann
Journal:  Diagn Microbiol Infect Dis       Date:  2012-06-22       Impact factor: 2.803

2.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

3.  Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007-2009 SENTRY Antimicrobial Surveillance Program.

Authors:  Robyn M Kaiser; Mariana Castanheira; Ronald N Jones; Fred Tenover; Ruth Lynfield
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-06       Impact factor: 2.803

4.  Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).

Authors:  Mariana Castanheira; Sarah E Farrell; Lalitagauri M Deshpande; Rodrigo E Mendes; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

Review 5.  ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.

Authors:  E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson
Journal:  Clin Microbiol Infect       Date:  2014-01       Impact factor: 8.067

6.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

Review 7.  New β-lactam-β-lactamase inhibitor combinations in clinical development.

Authors:  David M Shlaes
Journal:  Ann N Y Acad Sci       Date:  2013-01       Impact factor: 5.691

8.  Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Authors:  Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

Review 9.  Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens.

Authors:  Chang-Seop Lee; Yohei Doi
Journal:  Infect Chemother       Date:  2014-09-24

Review 10.  Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Authors:  Philippe Lagacé-Wiens; Andrew Walkty; James A Karlowsky
Journal:  Core Evid       Date:  2014-01-24
View more
  45 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

2.  Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.

Authors:  Kirk Nelson; Peera Hemarajata; Dongxu Sun; Debora Rubio-Aparicio; Ruslan Tsivkovski; Shangxin Yang; Robert Sebra; Andrew Kasarskis; Hoan Nguyen; Blake M Hanson; Shana Leopold; George Weinstock; Olga Lomovskaya; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.

Authors:  Romney M Humphries; Peera Hemarajata
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 4.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

5.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

6.  Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies.

Authors:  Michael J Satlin; Nina Cohen; Kevin C Ma; Zivile Gedrimaite; Rosemary Soave; Gülce Askin; Liang Chen; Barry N Kreiswirth; Thomas J Walsh; Susan K Seo
Journal:  J Infect       Date:  2016-07-09       Impact factor: 6.072

7.  In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

Authors:  Boudewijn L M de Jonge; James A Karlowsky; Krystyna M Kazmierczak; Douglas J Biedenbach; Daniel F Sahm; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 8.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

9.  In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

Authors:  Naoki Kohira; Joshua West; Akinobu Ito; Tsukasa Ito-Horiyama; Rio Nakamura; Takafumi Sato; Stephen Rittenhouse; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.